A few examples of "how" developmental cancer antibody companies make $$$ (from Patrys recent corporate overview). The "when" - well this will be dependent on the perceived quality of the asset (antibody) and/or the extent to which "de-risking" of the asset has occurred.
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 0 {colgroup} 1 {col}{/col}{col}{/col}{col}{/col}{col}{/col}{col}{/col}{col}{/col} 2 {/colgroup} 3 Date Tech Seller Buyer Total (USD) Up Front (USD) 4 Feb-14 Nanobody platform Ablynx Merck 6.5B 27 M 5 Jan-15 Checkpoint regulators: GITR, OX40, LAG-3 and TIM-3 Agenus Incyte 410M 60M 6 Aug-15 Anti-GDF15 MAb Aveo Oncology Novartis 326M 15M 7 Oct-15 Anti-TGF-beta MAb Xoma Novartis 480M 37M 8 Jan-16 Cell-penetrating alphabodies* Complix Merck 280M N/A 9 May-16 Bi-specific Ab, alternative to CAR-T Macro-Genics Janssen 740M 75M 10 Jul-16 4 early stage Abs Jounce Celgene 2.6B 261M 11 Jun-17 Intracellular delivery platform Feldan/Elasmogen Amgen N/A N/A 12 Nov-17 Bi-specific antibody platform Zymeworks J&J 332M 50M 13 April-18 Bi-specific antibody platform Compugen Astra Zeneca 210M 10M 14 April-18 Checkpoint inhibitor: OSE-172 a SIRP alpha antagonist OSE Immunotherapeutics Boehringer Ingelheim 1.4B 18.4M 15 *Collaboration expanded in 2017
A few examples of "how" developmental cancer antibody companies...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |